Dynavax Technologies Corporation announced the first clinical data for Heplisav investigational hepatitis B vaccine in chronic kidney disease patients. These data were presented in a poster session at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania.

Vaccinated with Heplisav, chronic kidney disease patients demonstrated rapid, increased protection against hepatitis B viral infection in fewer doses than patients receiving licensed vaccine. 96 per cent of patients (n = 36) receiving three doses of Heplisav achieved seroprotection at month seven, compared to 88 per cent of patients (n = 10) receiving 8 doses of Engerix-B. Dynavax recently began vaccinating chronic kidney disease patients with Heplisav in a phase-3 registration trial.

"For chronic kidney disease patients at increased risk of exposure to hepatitis B viral infection, achieving rapid and efficacious protection is critical," commented Shelly McNeil, Canadian Center for Vaccinology, Halifax, Nova Scotia and Principal Investigator. "A vaccine that provides faster, superior immunogenicity with a more convenient dosing regimen could offer significant clinical benefits for hyporesponsive chronic kidney disease patients and the dialysis centers that routinely immunize these patients."

Heplisav is a phase-3 adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases.